Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Poststroke cognitive impairment

Full Text:


Cognitive impairment (CI) is one of the leading causes of disability after stroke; CI is observed in more than half of patients and reaches a pronounced degree (of dementia) in every three to five patients. CI in poststroke patients is often caused not only by focal vascular lesions of the brain, but also by the presence of concomitant vascular and neurodegenerative diseases. The treatment and prevention of progressive CI are based on stroke prevention, non-drug and drug methods to improve cognitive functions. Blood pressure normalization during antihypertensive therapy is most effective in preventing the progression of CI in stroke patients. The use of Actovegin in patients with CI after stroke is discussed. The results of the author's own 5-year follow-up of 350 patients with stroke are presented.

About the Author

V. A. Parfenov
Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021


1. Gusev EI, Bogolepova AN. Kognitivnye narusheniya pri tserebrovaskulyarnykh zabolevaniyakh [Cognitive impairment in cerebrovascular diseases]. Moscow: MEDpress-inform; 2013. 180 p. (In Russ.)

2. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive disorders]. Moscow: Remedium; 2014. 224 p. (In Russ.)

3. Gaynor E, Rohde D, Large M, et al. Cognitive Impairment, Vulnerability, and Mortality Post Ischemic Stroke: A Five-Year Follow-Up of the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) Cohort. J Stroke Cerebrovasc Dis. 2018 Sep;27(9):2466-73. doi: 10.1016/j.jstrokecerebrovasdis.2018.05.002

4. Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011;42:2672-713. doi: 10.1161/STR.0b013e3182299496

5. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med. 2014;2(8):80-96.

6. Rist PM, Chalmers J, Arima H, et al. Baseline cognitive function, recurrent stroke, and risk of dementia in patients with stroke. Stroke. 2013;44:1790-5. doi: 10.1161/STROKEAHA.111.680728

7. Gutierrez Perez C, Savborg M, Pahlman U, et al. High frequency of cognitive dysfunction before stroke among older people. Int J Geriatr Psychiatry. 2011;26:622-9. doi:10.1002/gps.2573

8. Douiri A, Rudd AG, Wolfe CD. Prevalence of poststroke cognitive impairment: South London Stroke Register 1995–2010. Stroke. 2013;44:138-45. doi: 10.1161/STROKEAHA.112.670844

9. Jacquin A, Binquet C, Rouaud O, et al. Post-stroke cognitive impairment: high prevalence and determining factors in a cohort of mild stroke. J Alzheimers Dis. 2014;40:1029-38. doi: 10.3233/JAD-131580

10. Jokinen H, Melkas S, Ylikoski R, et al. Post-stroke cognitive impairment is common even after successful clinical recovery. Eur J Neurol. 2015; 22(9):1288-94. doi: 10.1111/ene.12743

11. O’Brien J, Ames D, Gustafson L, et al, eds. Cerebrovascular disease, cognitive impairment and dementia. Cerebrovascular disease and dementia. 2nd ed. London; N.Y.: Martin Dunitz; 2004.

12. Benisty S, Gouw AA, Porcher R, et al. Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. J Neurol Neurosurg Psychiatry. 2009;80: 478-83. doi: 10.1136/jnnp.2008.160440

13. Sachdev P, Kalaria R, O’Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-18. doi: 10.1097/WAD.0000000000000034

14. Jacova C, Pearce LA, Costello R, et al. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol. 2012;72:351-62. doi: 10.1002/ana.23733

15. Barker WW, Luis CA, Kashuba A. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4): 203-12. doi: 10.1097/00002093-200210000-00001

16. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8: 1006-18. doi: 10.1016/S1474-4422(09)70236-4

17. Altieri M, Di Piero V, Pasquini M, et al. Delayed poststroke dementia: a 4-year followup study. Neurology. 2004 Jun 22;62(12):2193-7. doi: 10.1212/01.WNL.0000130501.79012.1A

18. Gemmell E, Tam E, Allan L, et al. Neuron volumes in hippocampal subfields in delayed poststroke and aging-related dementias. J Neuropathol Exp Neurol. 2014;73:305-11. doi: 10.1097/NEN.0000000000000054

19. Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. Int J Stroke. 2012;7:61-73. doi: 10.1111/j.1747-4949.2011.00731.x

20. Mohd Zulkifly MF, Ghazali SE, Che Din N, et al. The influence of demographic, clinical, psychological and functional determinants on post-stroke cognitive impairment at day care stroke center, Malaysia. Malays J Med Sci. 2016;23(2):53-64.

21. Arba F, Quinn T, Hankey GJ, et al. Determinants of post-stroke cognitive impairment: analysis from VISTA. Acta Neurol Scand. 2017;135(6):603-7. doi: 10.1111/ane.12637

22. Sibolt G, Curtze S, Melkas S, et al. Poststroke dementia is associated with recurrent ischaemic stroke. J Neurol Neurosurg Psychiatry. 2013;84:722-6. doi: 10.1136/jnnp-2012-304084

23. Jellinger KA. The enigma of mixed dementia. Alzheimers Dement. 2007;3:40-53. doi: 10.1016/j.jalz.2006.09.002

24. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular Dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43: 250-60. doi: 10.1212/WNL.43.2.250

25. Oberlin LE., Waiwood AM, Cumming TB, et al. Effects of physical activity on post-stroke cognitive function: a meta-analysis of randomized controlled trials. Stroke. 2017 Nov;48(11): 3093-100. doi: 10.1161/STROKEAHA.117.017319

26. Ankolekar S, Geeganage C, Anderton P, et al. Clinical trials for preventing post stroke cognitive impairment. J Neurol Sci. 2010;299 (1-2):168-74. doi: 10.1016/j.jns.2010.08.052

27. Gorelick PB. Blood Pressure and the Prevention of Cognitive Impairment. JAMA Neurol. 2014;71:1211-3. doi: 10.1001/jamaneurol.2014.2014

28. Ihle-Hansen H, Thommessen B, Fagerland MW, et al. Blood pressure control to prevent decline in cognition after stroke. Vasc Health Risk Manag. 2015;11:311-6. doi: 10.2147/VHRM.S82839

29. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25:457-507. doi: 10.1159/000131083

30. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110. doi: 10.1161/STR.0000000000000158

31. Verbitskaya SV, Parfenov VA, Reshetnikov VA, et al. Post-stroke cognitive impairment (results of a 5-year follow-up). Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):37-42 (In Russ.) doi: 10.14412/2074-2711-2018-1-37-42

32. Mahon S, Parmar P, Barker-Collo S, et al. Determinants, prevalence, and trajectory of long-term post-stroke cognitive impairment. Results from a 4-year follow-up of the ARCOS-IV study. Neuroepidemiology. 2017;49(3-4):129-34. doi: 10.1159/000484606

33. Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med. 2014;275(3): 229-50. doi: 10.1111/joim.12178

34. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013; 31(6):1073-82. doi: 10.1097/HJH.0b013e3283603f53

35. Machicao F, Muresanu DF, Hundsberger H, et al. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci. 2012;322(1):222-7. doi: 10.1016/j.jns.2012.07.069

36. Herrmann WM, Bohn-Olszewsky WJ, Kuntz G. Actovegin infusion treatment in patients with primarily degenerative dementia of the Alzheimer type and multi-infarct dementia. Zeitschrift fü r Geriatrie. 1992;5:46-55.

37. Kanowski S, Kinzler E, Lehmann E, Schweizer A, Kuntz C. Confirmed Clinical Efficacy of Actoveginmin Elderly Patients with Organic Brain Syndrome. Pharmacopsychiat. 1995;28:125-33. doi: 10.1055/s-2007-979604

38. Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn A. ARTEMIDA trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017;48:1262-70. doi: 10.1161/STROKEAHA.116.014321

For citation:

Parfenov V.A. Poststroke cognitive impairment. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):22-27. (In Russ.)

Views: 111

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)